Audentes Therapeutics

Audentes Therapeutics is a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy, AT845 for the treatment of Pompe disease, AT342 for the treatment of Crigler-Najjar Syndrome, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia. The company focuses on the treatment of rare diseases caused by single gene, or monogenic, defects in DNA that can be addressed using gene therapy.
  • TickerBOLD
  • ISINUS05070R1041
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Astellas Boldly Goes Big With BOLD Acquisition; Downgrade to NEUTRAL

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Astellas Boldly Goes Big With BOLD Acquisition; Downgrade to NEUTRAL

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Nov 25 2019 6:27AM

1 director sold

A director at Audentes Therapeutics Inc sold 11,000 shares at 32.163USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

ValuEngine Rating and Forecast Report for BOLD

ResearchPool Subscriptions

Get the most out of your insights

Get in touch